Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15487329 | 0.92 | NPC1 (0.57) | NPC1RAB9ATDP1APPSMN1; SMN2 | |
| SCHEMBL31166913 | 0.86 | NPC1 (0.52) | NPC1RAB9ATDP1APPSMN1; SMN2 | |
| SCHEMBL20607956 | 0.86 | MAOB (0.49) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL17441687 | 0.82 | NPC1 (0.47) | NPC1RAB9ATDP1APPSMN1; SMN2 | |
| SCHEMBL17440686 | 0.81 | ERN1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL4706617 | 0.79 | NPC1 (0.59) | NPC1RAB9ATDP1APPSMN1; SMN2 | |
| SCHEMBL13377762 | 0.79 | NPC1 (0.58) | NPC1RAB9ATDP1APPSMN1; SMN2 | |
| SCHEMBL28624326 | 0.78 | LMNA (0.47) | ALDH1A1LMNAPOLB | |
| SCHEMBL190181 | 0.78 | MAOB (0.55) | NPC1RAB9ATDP1APPSMN1; SMN2 | |
| SCHEMBL1250536 | 0.77 | NPC1 (0.57) | NPC1RAB9ATDP1APPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246456-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | NPC1 1851/4885RAB9A 3499/4885TDP1 626/4885 |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | NPC1 1851/4885RAB9A 3499/4885TDP1 626/4885 |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | NPC1 2031/4885RAB9A 3663/4885TDP1 526/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | NPC1 2031/4885RAB9A 3663/4885TDP1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.